


ABOUT VERTEX PHARMACEUTICALS

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases (including FSGS). In addition, Vertex has a rapidly expanding investigational pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.



Commitment to Patients

- \$1.8 billion invested in R&D annually¹
- Serial innovation – 5 medicines approved in two therapeutic areas in less than ten years
- 7 disease areas under clinical study¹



Commitment to Communities

- \$36.7 million given through Vertex and the Vertex Foundation¹
- \$3.3 million donated by employees and the Vertex Foundation, with 1,192 employees donating¹
- \$5M given to COVID-19 relief
- Recognized as one of the 50 most community-minded companies in the United States by the Points of Light Foundation¹



Commitment to Diversity, Inclusion, & Equity

- \$4 million committed to racial and social justice, including helping to establish the Boston University Center for Antiracist Research¹
- Increased inclusion of underrepresented minority individuals in all areas of science and medicine through our partnership with the Biomedical Science Careers Program (BSCP)¹
- 44% of new hires in the US are racially and ethnically diverse¹

¹ Vertex 2020 Corporate Responsibility Report. <https://www.vrtx.com/sites/default/files/CR2020.pdf>